Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Mechanism of Action of a Small Molecule Inhibitor That Targets Usp9x Deubiquitinase Activity in Multiple Myeloma and Mantle Cell Lymphoma

Luke F. Peterson, PhD, Hanshi Sun, PhD, Matthew Young, PhD, Hollis D. Showalter, Ph.D., Andrzej J Jakubowiak, MD, PhD, Moshe Talpaz, MD, Nicholas Donato, PhD

Blood (2011) 118 (21): 1415.

https://doi.org/10.1182/blood.V118.21.1415.1415

Published: 2011

Journal Articles

Deubiquitinase Usp9X Regulates Cell Survival and Metabolic Signal Transduction in Multiple Myeloma Cells

Luke F. Peterson, PhD, Hanshi Sun, PhD, Vaibhav Kapuria, Ph.D., Malathi Kandarpa, PhD, Moshe Talpaz, MD, Andrzej J Jakubowiak, MD, PhD, Nicholas Donato, PhD

Blood (2011) 118 (21): 1835.

https://doi.org/10.1182/blood.V118.21.1835.1835

Published: 2011

Journal Articles

Inhibition of Usp9x Deubiquitinase Activity by WP1130 Reduces Mcl-1 Levels and Induces Apoptosis In Cells From Patients with Plasma Cell Dyscrasia and Drug-Refractory Multiple Myeloma

Hanshi Sun, PhD, Vaibhav Kapuria, Ph.D., Luke F. Peterson, PhD, Diane Giannola, Kandarpa Malathi, Ph.D., Moshe Talpaz, MD, Andrzej J Jakubowiak, MD, PhD, Nicholas Donato, PhD

Blood (2010) 116 (21): 3005.

https://doi.org/10.1182/blood.V116.21.3005.3005

Published: 2010

Journal Articles

The Novel BCR-ABL1 V304D Mutation Induces Pan-Tyrosine Kinase Inhibitor Resistance by a Unique Kinase Lateral Escape Mechanism and Is Associated with Very Poor Prognosis In Patients (PTS) with Chronic Myeloid Leukemia (CML).

Sabrina Pricl, PhD, Don L Gibbons, MD, PhD, Paola Posocco, PhD, Erik Laurini, PhD, Maurizio Fermeglia, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Jorge Cortes, MD, Matthew Young, PhD, Hanshi Sun, PhD, Luke F. Peterson, PhD, Nicholas Donato, PhD, Alfonso Quintás-Cardama, MD

Blood (2010) 116 (21): 3402.

https://doi.org/10.1182/blood.V116.21.3402.3402

Published: 2010

Journal Articles

In Silico modelling of Sensitivity to Novel Tyrosine Kinase Inhibitors of Highly Resistant Single and Polymutant BCR-ABL1 .

Sabrina Pricl, PhD, Don L Gibbons, MD, PhD, Paola Posocco, PhD, Erik Laurini, PhD, Maurizio Fermaglia, PhD, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Jorge Cortes, MD, Nicholas Donato, PhD, Alfonso Quintás-Cardama, MD

Blood (2010) 116 (21): 3388.

https://doi.org/10.1182/blood.V116.21.3388.3388

Published: 2010

Journal Articles

Mutational Analysis of Chronic Phase Chronic Myeloid Leukemia (CMLCP) Clones Reveals Heightened BCR-ABL1 Genetic Instability in Patients Failing Sequential Imatinib and Dasatinib Therapy.

Alfonso QuintasCardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop M. Kantarjian, MD, Moshe Talpaz, Nicholas Donato, PhD, Jorge Cortes, MD

Blood (2008) 112 (11): 2114.

https://doi.org/10.1182/blood.V112.11.2114.2114

Published: 2008

Journal Articles

Dasatinib Resistance in CML Patients. Identification of Novel BCR-ABL Kinase Domain Mutation.

Yelena Krijanovski, MD, Nicholas Donato, PhD, Alfonso Quintas-Cardama, MD, Jorge Cortes, MD, Moshe Talpaz, MD

Blood (2007) 110 (11): 1957.

https://doi.org/10.1182/blood.V110.11.1957.1957

Published: 2007

Journal Articles

A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling.

Vaibhav Kapuria, MS, Geoffrey Bartholomeusz, PhD, Ling-Yuan Kong, PhD, William Bornmann, PhD, Zhenghong Peng, PhD, Ashutosh Pal, PhD, David Maxwell, PhD, Moshe Talpaz, MD, Nicholas Donato, PhD

Blood (2007) 110 (11): 1556.

https://doi.org/10.1182/blood.V110.11.1556.1556

Published: 2007

Journal Articles

Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation.

Nicholas Donato, PhD, Vaibhav Kapuria, MS, Hanshi Sun, PhD, David Maxwell, PhD, Geoffrey Bartholomeusz, PhD, William Bornmann, PhD, Zhenghong Peng, PhD, Ashutosh Pal, PhD, Moshe Talpaz, MD

Blood (2007) 110 (11): 1003.

https://doi.org/10.1182/blood.V110.11.1003.1003

Published: 2007

Journal Articles

A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia.

Alfonso Quintas-Cardama, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Ji Wu, Feng Meng, Nicholas Donato, PhD

Blood (2006) 108 (11): 4773.

https://doi.org/10.1182/blood.V108.11.4773.4773

Published: 2006

NARROW

Mechanism of Action of a Small Molecule Inhibitor That Targets Usp9x Deubiquitinase Activity in Multiple Myeloma and Mantle Cell Lymphoma

Deubiquitinase Usp9X Regulates Cell Survival and Metabolic Signal Transduction in Multiple Myeloma Cells

Inhibition of Usp9x Deubiquitinase Activity by WP1130 Reduces Mcl-1 Levels and Induces Apoptosis In Cells From Patients with Plasma Cell Dyscrasia and Drug-Refractory Multiple Myeloma

The Novel BCR-ABL1 V304D Mutation Induces Pan-Tyrosine Kinase Inhibitor Resistance by a Unique Kinase Lateral Escape Mechanism and Is Associated with Very Poor Prognosis In Patients (PTS) with Chronic Myeloid Leukemia (CML).

In Silico modelling of Sensitivity to Novel Tyrosine Kinase Inhibitors of Highly Resistant Single and Polymutant BCR-ABL1 .

Mutational Analysis of Chronic Phase Chronic Myeloid Leukemia (CMLCP) Clones Reveals Heightened BCR-ABL1 Genetic Instability in Patients Failing Sequential Imatinib and Dasatinib Therapy.

Dasatinib Resistance in CML Patients. Identification of Novel BCR-ABL Kinase Domain Mutation.

A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling.

Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation.

A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only